Infliximab: A Treatment Option for Ulcerative Pyoderma Gangrenosum
- 0 Comments
- 3823 reads
Two patients (Patients 1 and 2) received three treatments, two patients (Patients 3 and 5) were administered a single infusion, and the final patient (Patient 4) received two treatments, the second of which was discontinued after the patient experienced flushing and pruritus. These symptoms subsided after the infliximab infusion was stopped. Adjunctive medications included cyclosporine A, systemic steroids, and topical tacrolimus.
All patients and 12 of 13 ulcers healed (Table 1). The mean time to heal was 12.2 weeks. Marked improvement occurred within one month. One patient indicated that the pain associated with the lesion had decreased by 50 percent within 24 hours of treatment, and the ulcer reduced in size by 50 percent 72 hours postinfusion. Interestingly, in that patient, repeated infusions were required for complete resolution. Although the PG ulcer of Patient 4 resolved with the first infusion of infliximab, treatment for a subsequent ulcer was discontinued after the patient experienced flushing and pruritus. These symptoms subsided after the infliximab infusion was stopped, and the ulcer eventually healed with systemic steroids. No other adverse effects occurred.
Table 1 and Figure 1 summarize the outcome of the five patients. Figures 2A and B are of Patient 4 before and after treatment with infliximab.
Five patients with 13 ulcers diagnosed with PG were treated with infliximab. All patients were unresponsive to or did not tolerate previous treatment, and the mean duration of disease was 6.6 months (range 1–17 months). Patients received a range of 1 to 3 infusions (mean 1.8). All patients and 12 of 13 ulcers healed with the infliximab monotherapy (2 patients) or as an adjuvant therapy (3 patients), with a mean time to heal of 12.2 weeks.
Infliximab is a chimeric monoclonal antibody that irreversibly binds to TNFa with a high affinity, thereby preventing TNFa from binding to its receptors. Infliximab is composed of the human immunoglobulin IgG constant region combined with the variable region of the mouse TNF monoclonal antibody. Produced by macrophages, neutrophils, eosinophils, and lymphocytes, TNFa acts as an inflammatory cytokine eliciting a variety of responses, including activation of other proinflammatory cytokines, which include interleukin-1 (IL-1), IL-6, and IL-8. This results in recruitment, migration, adhesion, and activation of other neutrophils, lymphocytes, and eosinophils and also induction of CD4 T-cell and macrophage cytotoxicity,[19–21] which, in turn, results in inflammation and tissue destruction.
Infliximab is usually tolerated well. Several adverse reactions have been reported, including headache, nausea, upper respiratory infections, abdominal pain, fatigue, and fever, which are some of the more commonly experienced reactions. In this series, one patient (Patient 4) developed flushing and pruritus, requiring discontinuation of therapy, whereby the symptoms subsided.
The long-term risks associated with infliximab are still largely undetermined. Although increases in tuberculosis, upper respiratory tract infections, and urinary tract infections have been reported, differences in mortality rates or severe infections following infliximab therapy have not. It is critical to obtain a chest radiograph and PPD prior to treatment, as the authors had in their patients. Infliximab may stimulate the production of antinuclear antibodies and antibodies to double-stranded DNA, but even in those cases development of clinical lupus syndrome is rare.
In conclusion, the authors report the clinical success of infliximab as both monotherapy and as adjuvant therapy for patients with PG. The TNFa antagonist provided rapid improvement and eventual resolution of the lesions associated with PG. However, larger, controlled studies are required to further examine the optimal dosing schedule, duration of improvement, and long-term effects of infliximab therapy.
1. Chaudhari U, Romano P, Mulcahy LD, et al. Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: A randomized trial. Lancet 2001;357:1842–7.
2. Ogilvie ALJ, Antoni C, Dechant C, et al. Treatment of psoriatic arthritis with antitumor necrosis factor alpha antibody clears skin lesions of psoriasis resistant to treatment with methotrexate. Br J Dermatol 2001;144:587–9.
3. Voigtlander C, Luftl M, Schuler G, Hertl M. Infliximab antitumor necrosis factor-alpha antibody): A novel, highly effective treatment of recalcitrant subcorneal pustular dermatosis (Sneddon-Wilkinson disease). Arch Dermatol 2001;137:1571–4.
4. Sullivan T, Welsh E, Kerdel FA, et al. Infliximab for hidradenitis suppurativa. Submitted for publication.
5. Kobbe G, Schneider P, Rohr U, et al. Treatment of severe steroid refractory acute graft-versus-host disease with infliximab, a chimeric human/mouse monoclonal antibody. Bone Marrow Transplant 2001;28:47–9.
6. Goosens PH, Verdburg RJ, Breedveld FC. Remission of Behçet’s syndrome with tumor necrosis factor-alpha blocking therapy. Rheumatic Dis 2001;60(6):637.
7. Robertson IP, Hickling P. Treatment of recalcitrant orogenital ulceration of Behçet’s syndrome with infliximab. Rheumatology 2001;40:473–4.
8. Baughman RP, Lower EE. Infliximab for refractory sarcoidosis. Sarcoidosis Vascular Lung Disease 2001;18(1):70.
9. Geyer AD, Anhalt GJ, Nossari HC. Effectiveness of infliximab in the treatment of refractory perineal cutaneous Crohn’s disease. Arch Dermatol 2000;136:459–60.
10. Mahadevan U, Sandborn WJ. Infliximab for the treatment of orofacial Crohn’s disease. Inflammatory Bowel Disease 2001;7(1):38–42.
11. Hughes AP, Jackson JM, Callen JP. Clinical features and treatment of peristomal pyoderma gangrenosum. J Am Med Assoc 2000;284:1546–8.
12. Botros N, Pickover L, Das KM. Image of the month: Pyoderma gangrenosum caused by ulcerative colitis. Gastroenterology 2000;118:654–809.
13. Bennett ML, Jackson JM, Jorizzo JL, et al. Pyoderma gangrenosum: A comparison of typical and atypical forms with an emphasis on time to remission. Medicine 2000;79(1):37–46.
14. Bennett CR, Brage ME, Mass DP. Pyoderma gangrenosum mimicking postoperative infection in the extremities. J Bone Joint Surg 1999;81:1013–8.
15. Powell RJ, Holbrook MR, Stevens A. Pyoderma gangrenosum and its treatment. Lancet 1997;350:1720–1.
16. Hurwitz RM, Haseman JH. The evolution of pyoderma gangrenosum: A clinicopathologic correlation. Am J Dermatopathol 1993;15:28–33.
17. Litvak D, Kirsner RS, Pakdaman NN, Federman DG. Pyoderma gangrenosum and myelodysplastic syndrome. South Med J 2000;93:923–5.
18. Chow RKP, Ho VC. Treatment of pyoderma gangrenosum. J Am Acad Dermatol 1996;34:1047–60.
19. Mouser JF, Hyams JS. Infliximab: A novel chimeric monoclonal antibody for the treatment of Crohn’s disease. Clin Ther 1999;21:932–42.
20. Old LJ. Tumor necrosis factor (TNF). Scientific Am 1988;258:59–60.
21. Dinarello CA. Proinflammatory cytokines. Chest 2000;118(2):503–7.
22. Schaible TF. Long-term safety of infliximab. Can J Gastroenterol 2000;14(supplement C):29C–32C.
23. Charles PJ, Smeenk RJ, De Jong J, et al. Assessment of antibodies to double stranded DNA induced in rheumatoid arthritis patients following treatment with infliximab monoclonal antibody to TNF alpha: Findings in label and randomized placebo controlled trials. Arthr Rheumatol 2000;43(11):23811–2.